JP2004512264A5 - - Google Patents

Download PDF

Info

Publication number
JP2004512264A5
JP2004512264A5 JP2002505023A JP2002505023A JP2004512264A5 JP 2004512264 A5 JP2004512264 A5 JP 2004512264A5 JP 2002505023 A JP2002505023 A JP 2002505023A JP 2002505023 A JP2002505023 A JP 2002505023A JP 2004512264 A5 JP2004512264 A5 JP 2004512264A5
Authority
JP
Japan
Prior art keywords
protein
type
heat shock
hpv
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002505023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004512264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/020240 external-priority patent/WO2002000242A2/en
Publication of JP2004512264A publication Critical patent/JP2004512264A/ja
Publication of JP2004512264A5 publication Critical patent/JP2004512264A5/ja
Withdrawn legal-status Critical Current

Links

JP2002505023A 2000-06-26 2001-06-26 ヒト乳頭腫ウイルスの治療法 Withdrawn JP2004512264A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21420200P 2000-06-26 2000-06-26
PCT/US2001/020240 WO2002000242A2 (en) 2000-06-26 2001-06-26 Human papilloma virus treatment

Publications (2)

Publication Number Publication Date
JP2004512264A JP2004512264A (ja) 2004-04-22
JP2004512264A5 true JP2004512264A5 (enExample) 2008-08-07

Family

ID=22798190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002505023A Withdrawn JP2004512264A (ja) 2000-06-26 2001-06-26 ヒト乳頭腫ウイルスの治療法

Country Status (27)

Country Link
US (4) US20020110566A1 (enExample)
EP (1) EP1296711B1 (enExample)
JP (1) JP2004512264A (enExample)
KR (2) KR100919266B1 (enExample)
CN (1) CN100441223C (enExample)
AT (1) ATE326236T1 (enExample)
AU (3) AU2001271449B2 (enExample)
BR (1) BR0111956A (enExample)
CA (1) CA2413543A1 (enExample)
CY (1) CY1105389T1 (enExample)
CZ (1) CZ20024154A3 (enExample)
DE (1) DE60119734T2 (enExample)
DK (1) DK1296711T3 (enExample)
EE (1) EE200200709A (enExample)
ES (1) ES2263637T3 (enExample)
HR (1) HRP20021015A2 (enExample)
HU (1) HUP0301308A3 (enExample)
IL (1) IL153474A0 (enExample)
MX (1) MXPA02012858A (enExample)
NO (1) NO20026044L (enExample)
NZ (1) NZ523408A (enExample)
PL (1) PL359930A1 (enExample)
PT (1) PT1296711E (enExample)
RU (1) RU2282461C2 (enExample)
SK (1) SK18362002A3 (enExample)
WO (1) WO2002000242A2 (enExample)
ZA (1) ZA200210211B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US6649402B2 (en) * 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CN1833030B (zh) 2003-05-22 2014-07-23 美国弗劳恩霍夫股份有限公司 用于表达、传递及纯化目标多肽的重组载体分子
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US7285386B2 (en) * 2003-10-29 2007-10-23 University Of New Mexico, And Educational Institution Of The State Of New Mexico RhPV as a model for HPV-induced cancers
DE10357677A1 (de) * 2003-12-10 2005-07-14 Greiner Bio-One Gmbh Primer und Sonden zum Nachweis genitaler HPV-Genotypen
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
RU2285537C1 (ru) * 2005-04-05 2006-10-20 Автономная некоммерческая организация "Институт молекулярной диагностики (АНО "ИнМоДи") Противоопухолевый пептидный препарат на основе фрагмента альфа-фетопротеина, его конъюгат, фармацевтическая композиция и способ лечения гормонзависимых опухолей
RU2283128C1 (ru) * 2005-04-05 2006-09-10 Сергей Викторович Луценко Способ получения препарата белка из семейства стрессовых и препарат белка hsp70, полученный этим способом
CN101189014A (zh) * 2005-04-27 2008-05-28 莱顿大学医学中心 用于治疗hpv诱导的上皮内瘤样病变的方法和手段
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
WO2007038083A2 (en) * 2005-09-21 2007-04-05 New York University Heat shock proteins from mycobacterium leprae and uses thereof
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
US8124103B2 (en) * 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
RU2316342C1 (ru) * 2006-03-31 2008-02-10 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинная композиция для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, способ его получения
BRPI0712729A2 (pt) * 2006-05-31 2013-07-02 Nventa Biopharmaceuticals Corp composiÇÕes hspe7 bioativas purificadas
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2008124483A1 (en) * 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
CN101687024A (zh) * 2007-04-28 2010-03-31 美国弗劳恩霍夫股份有限公司 锥虫抗原、疫苗组合物和相关方法
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
CA2736361C (en) * 2008-10-31 2017-10-10 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
BRPI0922301A2 (pt) * 2008-11-28 2019-02-26 Novartis Ag combinações de inibidor de hsp90
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激HIVTat誘導体ポリペプチドによる腫瘍治療
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US9662510B2 (en) 2010-07-19 2017-05-30 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
RU2438652C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального раствора для орошения, набор и способ его получения
RU2438702C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинальных капсул
RU2438703C1 (ru) * 2010-12-10 2012-01-10 Закрытое Акционерное Общество "Велес Фарма" Средство для лечения заболеваний шейки матки, ассоциированных с вирусом папилломы человека, в виде вагинального суппозитория
AU2012220592A1 (en) * 2011-02-23 2013-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Combined cell based GP96-IG-SIV/HIV, recombinant GP120 protein vaccination for protection from SIV/HIV
US9028884B2 (en) 2013-08-13 2015-05-12 Preventamedics LLC Medical delivery devices and methods for applying a barrier composition to a targeted skin surface
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
GB2541749B (en) 2015-08-31 2020-12-09 Emblation Ltd An interference suppression apparatus and method
US11497926B2 (en) 2016-08-08 2022-11-15 Emblation Limited Method and apparatus for the treatment, management and/or control of pain
EP3600551A1 (en) 2017-03-28 2020-02-05 Emblation Limited Stenosis treatment
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN108409866A (zh) * 2018-01-23 2018-08-17 合肥瑞城生生物科技有限公司 一种用于治疗和预防人乳头瘤病毒感染及相关疾病的多表位组合肽
CA3108739A1 (en) 2018-08-06 2020-02-13 Nielsen Biosciences, Inc. Treatment of warts
EP3909612A1 (en) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) * 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
NO172595C (no) 1983-02-07 1993-08-11 Battelle Memorial Institute Fremgangsmaate og ekspresjonsplasmid for fremstilling av hemagglutinin under kontroll av drosophila hsp-promoter
US4797359A (en) * 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
JPS62164696A (ja) 1986-01-06 1987-07-21 エフ.ホフマン ― ラ ロシュ アーゲー HTLV−3gag遺伝子の発現
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
EP0345299A1 (en) 1987-02-02 1989-12-13 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5204259A (en) * 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
ATE127345T1 (de) 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
AU5184190A (en) 1989-02-23 1990-09-26 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
CA2063414A1 (en) 1989-06-19 1990-12-20 Richard A. Young Vector-mediated genomic insertion and expression of dna in bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
WO1992008488A1 (en) 1990-11-08 1992-05-29 University College London Mycobacterium as adjuvant for antigens
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0521220A1 (en) 1991-06-14 1993-01-07 Institut Pasteur Recombinant immunogenic actinomycetale
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
EP0700445B1 (en) 1993-06-04 2002-01-23 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5404142A (en) 1993-08-05 1995-04-04 Analog Devices, Incorporated Data-directed scrambler for multi-bit noise shaping D/A converters
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
JP4163253B2 (ja) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
HUP9904137A3 (en) * 1996-07-29 2001-06-28 Cantab Pharmaceuticals Res Ltd Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
DE69735376T2 (de) 1996-11-26 2006-12-14 Stressgen Biotechnologies Corp., Victoria Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
CA2282426A1 (en) 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
HUP0003601A3 (en) * 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1248631A (zh) * 1998-09-24 2000-03-29 周国庆 一种免疫预防和免疫治疗性病和癌症的融合蛋白
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU5926700A (en) * 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
EP1218030A4 (en) 1999-09-10 2004-09-15 Univ Fordham METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TRANSPLANT REJECTION BY USING HEAT SHOCK PROTEINS
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU2001229592A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
AU2001229597A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
AU2001227960A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법

Similar Documents

Publication Publication Date Title
RU2003101965A (ru) Лечение инфекции, вызываемой вирусом папилломы человека
JP2004504057A5 (enExample)
US6066324A (en) Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
ES2263637T3 (es) Hpv-e7 para el tratamiento del papilomavirus humano.
JP3878197B2 (ja) 組換え乳頭腫ウイルスl1
JP2003500040A5 (enExample)
NZ538399A (en) Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
JP2006501825A5 (enExample)
US10300103B2 (en) Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating HPV infection and/or HPV-associated tumors, and mucosal immunity-inducing agent
CA2424700A1 (en) Genetic immunisation against cervical carcinoma
CN104379170B (zh) 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
JP2006507797A5 (enExample)
JP2002532434A5 (enExample)
JP2002502827A5 (enExample)
CN112409478A (zh) 一种广谱hpv抗体及其制备方法和应用
CN102199217A (zh) 乙型肝炎病毒多表位融合蛋白及其制备方法和应用
Mahdavi et al. Recent advances in human papillomavirus vaccines
US20260053900A1 (en) Use of virus-like particles in vaccination
WO2010056148A1 (ru) Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека
CN1696152A (zh) 大肠杆菌表达的人乳头瘤病毒16型l1e7重组蛋白
AU2003235191B2 (en) Papilloma virus-like particles, fusion proteins as well as processes for their production
Guo et al. Development Status and trend of HPV vaccine
KR20070078562A (ko) 대장균의 열에 불안정한 내독소의 b 서브유닛과 사람파필로마바이러스 16형 e7의 융합단백질 및 이의 용도
KR20070078559A (ko) 대장균의 열 불안정성 내독소 b 서브유닛과 사람파필로마바이러스 16형 e6의 단백질이 융합된 단백질 및이의 용도
HK1248108A1 (en) Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent